companydata.dkPerfusion Tech ApS: Financial statements 2024
CVR: 38238213
Perfusion Tech ApS (CVR 38238213) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -9,021,930 and a net result of DKK -14,469,520 compared with DKK -9,544,785 the year before. Equity amounted to DKK 2,114,073. The solvency ratio was 37.8%. The company had 11 employees in the financial year.
- Gross Profit
- -9,021,930 kr.
- Profit/Loss
- -14,469,520 kr.
- Equity
- 2,114,073 kr.
- Total Assets
- 5,585,408 kr.
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -9 mio. | -14.5 mio. | 2.1 mio. | 11 |
| 2023 | - | -5.4 mio. | -9.5 mio. | 2.9 mio. | 8 |
| 2022 | - | -4.2 mio. | -6.6 mio. | 1.2 mio. | 7 |
| 2021 | - | -1.1 mio. | -2.1 mio. | -3.9 mio. | 4 |
| 2020 | - | -1.1 mio. | -1.5 mio. | -1.8 mio. | 3 |
How creditworthy is Perfusion Tech ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2024
Perfusion Tech ApS has published its annual report for 2023. Gross profit came to DKK -5,414,376, and the net result was DKK -9,544,785.
As of March 13, 2024, Mads Aagaard Linde Madsen has joined the board of directors of Perfusion Tech ApS.
As of March 13, 2024, Morten Asp Vonsild Lund has left the board of directors of Perfusion Tech ApS.
About Perfusion Tech ApS
Perfusion Tech ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2016. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Perfusion Tech IVS. The management consists of Declan Cassells. The company is owned by Renew Pharmaceuticals Limited. In 2025, the company reported a gross profit of DKK -6,142,804 and a net result of DKK -12,724,708 compared with DKK -14,469,520 the year before. Equity amounted to DKK -9,640,655.